Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207016570> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4207016570 endingPage "453" @default.
- W4207016570 startingPage "448" @default.
- W4207016570 abstract "Ruxolitinib is an FDA-approved treatment of intermediate- and high-risk myelofibrosis. In the phase 3 COMFORT studies, ruxolitinib reduced spleen volume in patients with myelofibrosis, with a median time to response of 3 months. However, nearly 20% of patients discontinued by month 4 with few treatment options available following discontinuation of ruxolitinib treatment. In this study, 2 independent patient care data sources were queried (Cardinal Health Oncology Provider Extended Network [OPEN] and HealthCore Integrated Research Environment [HIRE®]), and a retrospective review of medical charts was conducted. Patients aged ≥18 years with a diagnosis of myelofibrosis (primary or secondary), use of ruxolitinib for myelofibrosis, and documented physician-directed ruxolitinib interruption were included. Among 26 included patients, pre-interruption median (interquartile range [IQR]) ruxolitinib treatment duration was 123 (57–391, OPEN) and 110 (37–148, HIRE) days. Half the patients interrupted treatment within 3 months, commonly for adverse events (42% and 71%, respectively). After restarting ruxolitinib, median (IQR) re-treatment duration was 196 (54–553) and 166 (108–262) days, respectively. Consistent with previous reports, symptoms and spleen size improved in (OPEN/HIRE) 45%/43% and 40%/33% of evaluable patients, respectively. Further studies investigating the management of dose modifications and interruptions are needed to optimize benefit from ruxolitinib therapy." @default.
- W4207016570 created "2022-01-26" @default.
- W4207016570 creator A5006893148 @default.
- W4207016570 creator A5017460979 @default.
- W4207016570 creator A5023728016 @default.
- W4207016570 creator A5031571414 @default.
- W4207016570 creator A5065936877 @default.
- W4207016570 creator A5085521139 @default.
- W4207016570 creator A5087187822 @default.
- W4207016570 creator A5088307376 @default.
- W4207016570 creator A5091492816 @default.
- W4207016570 date "2022-01-01" @default.
- W4207016570 modified "2023-09-27" @default.
- W4207016570 title "Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes" @default.
- W4207016570 cites W1989356964 @default.
- W4207016570 cites W2018254868 @default.
- W4207016570 cites W2115351357 @default.
- W4207016570 cites W2121743767 @default.
- W4207016570 cites W2159595282 @default.
- W4207016570 cites W2418937816 @default.
- W4207016570 cites W2622547803 @default.
- W4207016570 cites W2810060832 @default.
- W4207016570 cites W2917031389 @default.
- W4207016570 cites W3024154112 @default.
- W4207016570 cites W3119071615 @default.
- W4207016570 cites W3120572889 @default.
- W4207016570 doi "https://doi.org/10.1159/000520440" @default.
- W4207016570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35008087" @default.
- W4207016570 hasPublicationYear "2022" @default.
- W4207016570 type Work @default.
- W4207016570 citedByCount "3" @default.
- W4207016570 countsByYear W42070165702022 @default.
- W4207016570 countsByYear W42070165702023 @default.
- W4207016570 crossrefType "journal-article" @default.
- W4207016570 hasAuthorship W4207016570A5006893148 @default.
- W4207016570 hasAuthorship W4207016570A5017460979 @default.
- W4207016570 hasAuthorship W4207016570A5023728016 @default.
- W4207016570 hasAuthorship W4207016570A5031571414 @default.
- W4207016570 hasAuthorship W4207016570A5065936877 @default.
- W4207016570 hasAuthorship W4207016570A5085521139 @default.
- W4207016570 hasAuthorship W4207016570A5087187822 @default.
- W4207016570 hasAuthorship W4207016570A5088307376 @default.
- W4207016570 hasAuthorship W4207016570A5091492816 @default.
- W4207016570 hasBestOaLocation W42070165701 @default.
- W4207016570 hasConcept C119060515 @default.
- W4207016570 hasConcept C126322002 @default.
- W4207016570 hasConcept C141071460 @default.
- W4207016570 hasConcept C197934379 @default.
- W4207016570 hasConcept C2776112149 @default.
- W4207016570 hasConcept C2778715236 @default.
- W4207016570 hasConcept C2780007613 @default.
- W4207016570 hasConcept C2780076729 @default.
- W4207016570 hasConcept C71924100 @default.
- W4207016570 hasConceptScore W4207016570C119060515 @default.
- W4207016570 hasConceptScore W4207016570C126322002 @default.
- W4207016570 hasConceptScore W4207016570C141071460 @default.
- W4207016570 hasConceptScore W4207016570C197934379 @default.
- W4207016570 hasConceptScore W4207016570C2776112149 @default.
- W4207016570 hasConceptScore W4207016570C2778715236 @default.
- W4207016570 hasConceptScore W4207016570C2780007613 @default.
- W4207016570 hasConceptScore W4207016570C2780076729 @default.
- W4207016570 hasConceptScore W4207016570C71924100 @default.
- W4207016570 hasIssue "4" @default.
- W4207016570 hasLocation W42070165701 @default.
- W4207016570 hasLocation W42070165702 @default.
- W4207016570 hasLocation W42070165703 @default.
- W4207016570 hasOpenAccess W4207016570 @default.
- W4207016570 hasPrimaryLocation W42070165701 @default.
- W4207016570 hasRelatedWork W2547101781 @default.
- W4207016570 hasRelatedWork W2731573311 @default.
- W4207016570 hasRelatedWork W3120572889 @default.
- W4207016570 hasRelatedWork W3141140978 @default.
- W4207016570 hasRelatedWork W3165639147 @default.
- W4207016570 hasRelatedWork W4207016570 @default.
- W4207016570 hasRelatedWork W4221100544 @default.
- W4207016570 hasRelatedWork W4251586583 @default.
- W4207016570 hasRelatedWork W4283399567 @default.
- W4207016570 hasRelatedWork W4385344054 @default.
- W4207016570 hasVolume "145" @default.
- W4207016570 isParatext "false" @default.
- W4207016570 isRetracted "false" @default.
- W4207016570 workType "article" @default.